213 related articles for article (PubMed ID: 20484421)
1. Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma.
Nayak TK; Garmestani K; Baidoo KE; Milenic DE; Brechbiel MW
J Nucl Med; 2010 Jun; 51(6):942-50. PubMed ID: 20484421
[TBL] [Abstract][Full Text] [Related]
2. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.
Nayak TK; Regino CA; Wong KJ; Milenic DE; Garmestani K; Baidoo KE; Szajek LP; Brechbiel MW
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1368-76. PubMed ID: 20155263
[TBL] [Abstract][Full Text] [Related]
3. PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A″-DTPA-bevacizumab.
Nayak TK; Garmestani K; Baidoo KE; Milenic DE; Brechbiel MW
Int J Cancer; 2011 Feb; 128(4):920-6. PubMed ID: 20473899
[TBL] [Abstract][Full Text] [Related]
4. PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab.
Nayak TK; Garmestani K; Milenic DE; Brechbiel MW
J Nucl Med; 2012 Jan; 53(1):113-20. PubMed ID: 22213822
[TBL] [Abstract][Full Text] [Related]
5. HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts.
Nayak TK; Garmestani K; Milenic DE; Baidoo KE; Brechbiel MW
PLoS One; 2011 Mar; 6(3):e18198. PubMed ID: 21464917
[TBL] [Abstract][Full Text] [Related]
6. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.
Bhattacharyya S; Kurdziel K; Wei L; Riffle L; Kaur G; Hill GC; Jacobs PM; Tatum JL; Doroshow JH; Kalen JD
Nucl Med Biol; 2013 May; 40(4):451-7. PubMed ID: 23454247
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent.
Ray GL; Baidoo KE; Wong KJ; Williams M; Garmestani K; Brechbiel MW; Milenic DE
Br J Pharmacol; 2009 Aug; 157(8):1541-8. PubMed ID: 19681874
[TBL] [Abstract][Full Text] [Related]
8. A comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal (90)Y.
Price EW; Edwards KJ; Carnazza KE; Carlin SD; Zeglis BM; Adam MJ; Orvig C; Lewis JS
Nucl Med Biol; 2016 Sep; 43(9):566-576. PubMed ID: 27419360
[TBL] [Abstract][Full Text] [Related]
9. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
[TBL] [Abstract][Full Text] [Related]
10. In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice.
Schneider DW; Heitner T; Alicke B; Light DR; McLean K; Satozawa N; Parry G; Yoo J; Lewis JS; Parry R
J Nucl Med; 2009 Mar; 50(3):435-43. PubMed ID: 19223400
[TBL] [Abstract][Full Text] [Related]
11. (90) Y/(177) Lu-labelled Cetuximab immunoconjugates: radiochemistry optimization to clinical dose formulation.
Chakravarty R; Chakraborty S; Sarma HD; Nair KV; Rajeswari A; Dash A
J Labelled Comp Radiopharm; 2016 Jul; 59(9):354-63. PubMed ID: 27264196
[TBL] [Abstract][Full Text] [Related]
12. Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody.
Shin IS; Lee SM; Kim HS; Yao Z; Regino C; Sato N; Cheng KT; Hassan R; Campo MF; Albone EF; Choyke PL; Pastan I; Paik CH
Nucl Med Biol; 2011 Nov; 38(8):1119-27. PubMed ID: 21741258
[TBL] [Abstract][Full Text] [Related]
13. Orthotopic pleural mesothelioma in mice: SPECT/CT and MR imaging with HER1- and HER2-targeted radiolabeled antibodies.
Nayak TK; Bernardo M; Milenic DE; Choyke PL; Brechbiel MW
Radiology; 2013 Apr; 267(1):173-82. PubMed ID: 23329660
[TBL] [Abstract][Full Text] [Related]
14. Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.
Milenic DE; Wong KJ; Baidoo KE; Nayak TK; Regino CA; Garmestani K; Brechbiel MW
MAbs; 2010; 2(5):550-64. PubMed ID: 20716957
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of [(111/114m)In]CHX-A''-DTPA-ZHER2:342, an affibody ligand coniugate for targeting of HER2-expressing malignant tumors.
Orlova A; Rosik D; Sandström M; Lundqvist H; Einarsson L; Tolmachev V
Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):314-23. PubMed ID: 17464277
[TBL] [Abstract][Full Text] [Related]
16. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.
Ping Li W; Meyer LA; Capretto DA; Sherman CD; Anderson CJ
Cancer Biother Radiopharm; 2008 Apr; 23(2):158-71. PubMed ID: 18454685
[TBL] [Abstract][Full Text] [Related]
17. Preparation of
Pandey U; Kameswaran M; Gamre N; Dash A
J Labelled Comp Radiopharm; 2019 Apr; 62(4):158-165. PubMed ID: 30663095
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
